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Envelope processing and incorporationUnderstanding the properties of viruses capable of establishing infection during perinatal transmission of
HIV-1 is critical for designing effective means of limiting transmission. We previously demonstrated that the
newly transmitted viruses (in infant) were more ﬁt in growth, as imparted by their envelope glycoproteins,
than those in their corresponding mothers. Here, we further characterized the viral envelope glycoproteins
from six mother–infant transmission pairs and determined whether any speciﬁc envelope functions
correlate with HIV-1 subtype C perinatal transmission. We found that most newly transmitted viruses were
less susceptible to neutralization by their maternal plasma compared to contemporaneous maternal viruses.
However, the newly transmitted variants were sensitive to neutralization by pooled heterologous plasma but
in general were resistant to IgG1 b12. Neither Env processing nor incorporation efﬁciency was predictive of
viral transmissibility. These ﬁndings provide further insight into the characteristics of perinatally
transmissible HIV-1 and may have implications for intervention approaches., School of Biological Sciences,
ox 830666, Lincoln, NE 68583-
.
ll rights reserved.© 2009 Elsevier Inc. All rights reserved.Introduction
Mother-to-child transmission (MTCT) of HIV-1 is the primary
mode of pediatric HIV-1 infection and remains a signiﬁcant problem
in developing countrieswhere anti-retroviral therapy (ART) is still not
widely available. HIV-1-infected children account for 20% of all HIV-1-
related deaths (Luzuriaga and Sullivan, 2002). More than two thirds of
new HIV-1 infections occur in sub-Saharan Africa and 60% of these
infections are with HIV-1 subtype C with a signiﬁcant number of
infections in infants and children. HIV-1 subtype C is currently
responsible for the vast majority of new HIV-1 infections worldwide
(http:// www.unaids.org). However, factors that contribute to the
continuing expansion of subtype C viruses have yet to be clearly
elucidated.
It has been shown that subtype C viruses display biological
properties, such as restricted CCR5 usage and reduced replicative
capacity that distinguish it from other subtypes (Abebe et al., 1999;
Abraha et al., 2009; Ball et al., 2003; Bjorndal et al., 1999; Neilson et al.,1999; Zhang et al., 2006). Such differencesmay contribute to the rapid
spread and predominance of subtype C HIV-1 in sub-Saharan Africa
(Abraha et al., 2009; Ndung'u, Renjifo, and Essex, 2001). Sincemany of
these parameters are inﬂuenced by the HIV-1 envelope (Env)
glycoprotein, we and others have suggested that subtype C viruses
might have Env glycoproteins that are atypical in structure or function
compared to viruses from other HIV-1 subtypes (Cilliers et al., 2003;
Zhang et al., 2006). Whether the observed differences in cellular
tropism, transmission and pathogenetic outcome between subtype C
and other subtypes correlate with biological or genetic properties of
the Env glycoprotein has not been resolved. Previous studies of HIV-1
transmission, including sexual transmission and MTCT, have mainly
focused on evaluating the genotypic and antigenic properties of
transmitted variants but have provided little information on potential
correlations between Env function and MTCT (Derdeyn et al., 2004;
Dickover et al., 2006; Haaland et al., 2009; Kliks et al., 1994; Rainwater
et al., 2007; Scarlatti et al., 1993a; Wolinsky et al., 1992; Wu et al.,
2006). In addition, our understanding of perinatal transmission in
infants is mainly derived from studies of subtype B or other non-
subtype C HIV-1. The applicability of such ﬁndings to subtype C
remains to be substantiated. Given the high prevalence of subtype C
infections, a complete understanding of virus transmission and
identiﬁcation of factors that may affect the transmission of subtype
C HIV-1 are of importance.
Table 1
Summary of mother and infant transmission pairs.
Patient ID Subject Infant's ﬁrst HIV-PCR
positive timea
Time point
analyzed b
No. of clones
analyzed
1449 Mother N/A M00 2
Infant 2 mo 2 mo 2
2669 Mother N/A M00 3
Infant 2 mo 2 mo 5
2873 Mother N/A M00 4
Infant 2 mo 2 mo 4
2617 Mother N/A M00 5
Infant 2 mo 2 mo 4
1984 Mother N/A M00 7
Infant 4 mo 4 mo 6
1084 Mother N/A M00 4
Infant 6 mo 6 mo 3
N/A means that this category is not applicable to maternal subjects.
a Months after birth.
b M00: maternal samples at delivery were deﬁned as baseline.
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dominant feature during MTCT (Ahmad et al., 1995; Dickover et al.,
2001; Scarlatti et al., 1993b; Wolinsky et al., 1992; Zhang et al., 2002).
However, the basis of the observed genetic bottleneck remains poorly
deﬁned and the factors governing variant selection are largely
unknown. The bottleneck transmission has been attributed to various
factors including speciﬁc viral selection (Wolinsky et al., 1992) and
neutralization resistance of the transmitted viruses (Dickover et al.,
2006; Kliks et al., 1994; Scarlatti et al., 1993a; Wu et al., 2006).
Recently, we demonstrated that in infected mother–infant pairs
(MIPs), the newly transmitted viruses, those in infants, were selected
to have higher ex vivo ﬁtness, as imparted by their envelope
glycoproteins, than viruses from their corresponding chronically
infected maternal donors. Our study showed that the Env V1–V5
region was sufﬁcient to confer the higher replicative ﬁtness
phenotype (Kong et al., 2008). Genetic analyses indicated a signiﬁcant
viral bottleneck during perinatal transmission among the MIPs
analyzed (Zhang et al., submitted for publication). Since all the
mother and infants are anti-retroviral naive, these MIPs provide a
setting in which to examine the biological properties of transmitted
viruses and investigate the correlates of subtype C HIV-1 perinatal
transmission without additional selective pressure. Here, we further
explored the relationships between Env biological functions, such as
synthesis and processing, incorporation, or susceptibility to antibody
neutralization and the likelihood to achieve transmission through the
maternal–infant bottleneck. We found that in the majority of cases,
the newly transmitted viruses from the infant were less susceptible
to neutralization by their maternal plasma compared with contem-
poraneous maternal viruses, but no correlation between Env
processing or incorporation efﬁciency and transmissibility was
detected. These results, in conjunction with our previous studies,
suggest that viruses with the higher replication ﬁtness and lower
susceptibility to neutralization by the maternal plasma were
selectively transmitted during subtype C HIV-1 perinatal transmis-
sion. These ﬁndings provide further insight into the characteristics of
perinatally transmissible HIV-1 and also provide important informa-
tion relevant to the development of effective vaccine intervention
strategies.
Results
HIV-1 infected mother–infant pairs
The genetically characterized HIV-1 subtype C Env sequences
from six pre-existing mother–infant pairs (MIPs 2617, 1449, 1084,
2669, 2873 and 1984; Zhang et al., 2006) were used as source
materials for generation of Env chimeras. These infants were all
negative at birth for HIV-1 by both viral isolation and PCR, but were
found to be HIV-1 positive at either 2 months (2617, 1449, 2669 and
2873) or 4 months (1084 and 1984) after birth. Thus, HIV-1
transmission most likely occurred either during delivery or through
breastfeeding. Because the amount of sample from these children
was limited, priority was given to viral isolation in lieu of PCR when
necessary (e.g., infant 1084, viral isolation was positive by 4 months
but the ﬁrst PCR was performed 6 months after birth). The ﬁrst PCR-
positive time point from each infant is indicated in Table 1 along with
the time points studied and the number of clones analyzed for each
patient.
Co-receptor usage and cell tropism of patient-derived viruses
Previously, we demonstrated that the primary viral isolates from
these patients studied here exclusively used CCR5 as co-receptor,
exhibited macrophage tropism, and did not infect T-cell lines or form
syncytia in vitro (Zhang et al., 2006). To ensure that the characterized
Env sequences possessed co-receptor usage properties consistentwith those deﬁned for cognate viruses isolated by co-culture, we
generated infectiousmolecular clones in HIV-1 NL4-3 bearing patient-
derived Env V1–V5 region. Co-receptor usage of the chimeric
infectious molecular clones was tested in Ghost cell lines expressing
different co-receptors. Consistent with what we observed for the
primary isolates, all chimeric viruses exhibited CCR5 tropism and did
not form syncytia with the MT-2 cells (data not shown).
Biosynthesis and processing of patient-derived Env glycoprotein
The HIV-1 Env glycoprotein is synthesized as a 160-kDa precursor
protein, gp160, that is cleaved by cellular proteases during trafﬁcking
to the plasma membrane to generate the mature surface glycoprotein
gp120 and the transmembrane glycoprotein gp41. Thus the efﬁciency
of glycoprotein synthesis and cleavage could impact glycoprotein
availability for incorporation into particles, and therefore the
infectivity of those particles. The kinetics of synthesis and processing
of patient-derived Env glycoproteins was analyzed in COS-1 cells by
pulse-chase analysis. The results of two representative pairs are
shown in Fig. 1 and the rest are shown in Supplementary Fig. 1. The
glycoprotein from maternal and infant variants was synthesized and
processed over the course of a 24 h chase, as evidenced by the decay of
labeled gp160 concomitant with the increase of gp120 and gp41 in the
cell lysates (Fig. 1A and Supplementary Fig. 1A). However, only a
small fraction of the precursor gp160 was processed into the mature
gp120. The amount of gp120 detected in the supernatants increased
over the chase period indicating shedding from the plasmamembrane
after glycoprotein processing (Fig. 1B and Supplementary Fig. 1B). As
early as at 2 h of chase, the gp120 and gp41 appeared in cell lysates,
and gp120 was observed in supernatants derived from all the Env
expression clones (Fig. 1A and B; Supplementary Fig. 1A and B). Slight
differences in electrophoretic mobility of gp120, which could be
attributed to differences in the extent of N-glycosylation, were
observed for different chimeras in both cell lysates and supernatants
(Fig. 1A and B; Supplementary Fig. 1A and B). Nevertheless, no
obvious pattern in Env synthesis and processing that could distinguish
the transmitted (infant) from non-transmitted (mother) viruses,
despite differences in the level of expression and extent of processing
among chimeras.
Infectivity of maternal and infant chimeric viruses
In order to evaluate the ability of each Env glycoprotein to mediate
viral infectivity, we generated patient Env V1–V5 region-bearing
viruses by transfection of 293 T cells. The resulting virus-containing
supernatants were normalized for p24 content and were used to
infect TZM-bl indicator cells. Differential infectivity phenotypes were
Fig. 1. Synthesis and processing of Env glycoproteins gp160 and gp120 of two representative MIPs 1084 and 2617. COS-1 cells expressing chimeric Env proteins bearing patient-
derived Env V1–V5 region were pulse-labeled with [35S]methionine at 37 °C for 40 min. Cells were resuspended in complete medium and chased for varying times as indicated (h).
Cell lysates and supernatant were immunoprecipitated with pooled anti-HIV-1 antisera. Viral proteins from cell lysates (A) and supernatant (B) were resolved by SDS-PAGE.
166 H. Zhang et al. / Virology 400 (2010) 164–174observed among transmitted and non-transmitted viruses (Fig. 2). For
most patient-derived chimeras, with the exception of MIP 2669, the
viral infectivity was either slightly lower (MIP 1449 and 2617 Env) or
higher (MIP 1084 and 2617) relative to NL4-3 having wild-type Env.
There were also some patient-derived viruses that exhibited much
lower infectivity (1084 i6m-3 and 2669M0-3) or almost no detectable
infectivity (2617 i2m-3) when compared to the NL4-3. These
differences in infectivity did not always parallel their fusion capacity,
since higher Env-mediated fusogenicity did not always link to
efﬁcient viral infectivity (data not shown). Importantly, the differen-
tial level of viral infectivity observed amongmother and infant viruses
did not segregate the transmitted from non-transmitted viruses,
suggesting a lack of correlation between the viral infectivity and
transmissibility.
Replication kinetics of maternal and infant chimeric viruses
The ability of the chimeric viruses derived from each mother–
infant pair to establish a productive infection in TZM-bl cells was
compared (Fig. 3). Equivalent infectious units of each chimeric virus
were used to infect the cells, and replication levels were determined
by measuring the luciferase activity from the infected TZM-bl cells.
NL4-3 which was used as control replicated to a higher level relative
to most patient-derived chimeric viruses. It also displayed a steady
increase in the replication for the duration of the experiment in TZM-
bl cells (Figs. 3A–D). There were also a few patient-derived viruses
that replicated as well as NL4-3 (MIP 2617M0-3, i2m-4 and 2669M0-
2 and i2m-3). In addition, there were some maternal and infantviruses that were unable to establish a productive infection in TZM-bl
cells, such as 1084 i6m-3, 2671 i2m-3 and 2669 M0-3. In general, the
replication kinetics was variable between different patient isolates
and within the MIPs with no distinct patterns being observed except
that most patient Env chimera viruses replicated less well than the
subtype B NL4-3.
Incorporation of viral Env into viral particles
Our investigation of Env synthesis and processing analyses
revealed no correlations with transmission, but glycoprotein proces-
sing is not always coupled to effective incorporation or function
(Dubay et al., 1995). To investigate whether the level of Env
incorporation into virions contributed to differences in infectivity or
correlated with transmission, we used monoclonal antibody 2F5 to
detect the quantity of gp41 incorporated into virions. We chose to
quantify Env incorporation using gp41 detection since a speciﬁc and
sensitive anti-subtype C gp120 antibody was not available and all
chimeras share a common gp41 sequence derived from NL4-3.
Densitometry analyses of the blots indicated that different levels of
gp41 were incorporated into chimeric viral particles from the MIPs, as
calculated from gp41/p24 ratio (Fig. 4). For example, with 2617i2m-3
and 2669 M0-3, where poor Env incorporation was observed (Fig. 4C
and D), the virions also exhibited low infectivity and replication
deﬁcits resulted (Figs. 2C and D and Figs. 3C and D). For most chimeric
viruses, particularly forMIP 2617, such asM0-2, 3, 5 and i2m-2, higher
levels of Env in the virions correlated with greater infectivity (Fig. 4
and Fig. 2). However, the differential infectivity cannot be simply
Fig. 2. Relative infectivity of chimeric viruses from representative pairs. Chimeric
viruses bearing patient-derived Env V1–V5 region or NL4-3 were produced by
transfection of 293 T cells with the indicated proviral constructs and normalized to
p24. Two nanograms of p24 of each virus was used to infect TZM-bl target cells in
triplicates in the presence of 40 μg/ml of DEAE-dextran as described in Material and
methods. After 48 h post-infection, cells were lysed and luciferase activity was
measured. The infectivity of NL4-3 was set at 100, the infectivity of patient-derived
chimeric viruses was calculated relative to this value.
Fig. 3. Replication kinetics of chimeric viruses from representative pairs. Equal amount
of infectious unit from each chimeric virus-bearing patient-derived Env V1–V5 region
was used to infect TZM-bl cells. NL4-3 was used as control. Cell-free supernatant was
collected and assayed for replication kinetics at indicated days post-infection. The level
of viral replication was determined by infection TZM-bl cells by viruses harvested from
days 2, 4, 6, 8, 10, 12 and 14. After 48 h post-infection, cells were lysed and luciferase
activity was measured.
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to differences in inherent infectivity potency, as observed with 1084
i6m-3 and 2669 i2m-4, where poor infection or replication kinetics
were observed although substantial levels of Env were incorporated
into the particles (Figs. 2A and D; Figs. 3A and D; Figs. 4A and D). For
others, only a small fraction of the Env incorporated into the HIV-1
particles was sufﬁcient for infection. This can be seenwith 1084M0-3,
1084 i6m-2 and 1449 M0-2 (Figs. 4A and B; Figs. 2A and B). Despite
variability in incorporation of Env into the virions, no identiﬁable
pattern in the level of Env incorporation segregated maternal from
infant chimeras.
Sensitivity of maternal and infant envelope variants to neutralization by
maternal plasma
One of the primary selective pressure acting on Env is neutralizing
antibodies (nAbs). MTCT is unique in that it occurs in the presence of
passively acquired maternal antibody before birth. This passive
transfer of maternal antibodies to infants could play a role in the
selection of transmitted viruses with an nAb escaped phenotype.
Therefore, we determined the sensitivity of mother–infant Env-
chimera viruses to neutralization with maternal baseline plasma
collected at delivery. A total of 49 functional Env chimeras were tested
for their sensitivity to neutralization by maternal baseline plasma.Among the six MIPs tested, the maternal variants of 1984, 1084, 2873,
1449 and 2669 were generally sensitive to the maternal plasma;
infant viruses, in contrast, were more neutralization-resistant, as
indicated by their lower median inhibitory concentrations (IC50)
(Fig. 5A). Among the infants tested, infant 2669 harbored relative
sensitive variants with higher IC50 compared to those of other infant
variants. For MIP 2617, both mother and infant variants displayed
very low or undetectable neutralization by the maternal plasma,
although it is possible that this is due to the lack of effective
neutralization response in the mother (Fig. 5A). When the six pairs
were considered in aggregate, the IC50 value of variants from the
infants (median 77) was signiﬁcantly lower than that from the
mothers' (median 406; P=0.03; Mann–Whitney test), indicating that
the transmitted variants were more resistant than the mother's virus
population to maternal time-of-delivery plasma (Fig. 5B). Taken
together, our results indicate that neutralization resistant subtype C
HIV-1 variants have a higher probability of achieving perinatal
transmission, even though variants which are susceptible to nAbs
could also be transmitted.
Fig. 4. Incorporation of patient-derived Env glycoprotein into infectious virions. 293 T
cells were transfected with the indicated proviral expression constructs and the
resulting chimeric viruses bearing patient-derived Env V1–V5 region were collected at
48 h post-transfection. The viruses were pelleted through a 20% (wt/wt) sucrose
cushion by ultracentrifugation from the clariﬁed supernatants and the viral proteins
were analyzed by Western blot. Gp41 protein was detected by anti-gp41 mAb 2F5, and
p24 was detected by using anti-p24 mAb. Bands corresponding to gp41 and p24 are
indicated. Env incorporation into virions was calculated as gp41/p24 ratio. For each
pair, the NL4-3 value was set at 1, the relative Env incorporation for each virus was
calculated relative to this value. UN means that the signal is undetectable.
Fig. 5. Neutralization sensitivity of envelope variants for maternal plasma. (A)
Comparison of neutralization IC50 of maternal (○) and infant (Δ) variants bearing
patient-derived Env V1–V5 region for each transmission pair. The baseline maternal
plasma was tested at a starting dilution of 1:50 as indicated by the dashed horizontal
line. The luciferase activity obtained for each virus in the absence of serum was set to
100%, and the neutralization of the test plasma was calculated relative to this value. The
IC50 was deﬁned as the dilution of plasma that causes 50% inhibition of virus infection.
The horizontal bars indicate the median IC50 value for each individual. (B) Comparison
of IC50 between the mother (○) and infant (Δ) variants. The P value of the comparison
is shown. The horizontal bars indicate the median IC50 value. The dashed horizontal line
indicates the lowest dilution tested.
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heterologous antisera
We further assessed the neutralization sensitivity of the MIP
viruses using a pooled subtype C HIV-1 infected patient serum to
determine if they differed in their sensitivity to neutralization by
heterologous antibodies. Comparisons of neutralization sensitivity to
pooled HIV-1 plasma indicated that the pooled heterologous plasma
was very effective in neutralizing the variants from both mother
(median IC50, 1089) and infant (median IC50, 832), suggesting that
none of the infant variants were inherently resistant to neutralization.
However, the neutralization proﬁle varied among different pairs (Fig.
6A). Some maternal viruses showed higher susceptibility to the
heterologous pooled plasma than did their infant variants (MIPs 1984,
2873 and 2669), while some infant viruses were tended to be more
susceptible than those in their corresponding mothers (MIP 1084), or
viruses from both mother and infant were comparable in their
neutralization sensitivity (MIPs 1449 and 2617) (Fig. 6A). Notably, for
MIP 2617, all the mother and infant variants were neutralized by
pooled plasma, although they all showed very poor neutralization
when tested with the maternal plasma, indicating that neutralization
resistance is not an intrinsic property of these viruses (Fig. 6A).
However, statistical analysis of all the viral variants indicated that
there were no signiﬁcant differences in the sensitivity of the mother
and infant variants to neutralization by pooled heterologous plasma
although there was a trend toward the infant variants being more
resistant to the neutralization by the pooled plasma than thematernal
variants (Fig. 6B, P= 0.07; Mann–Whitney test). Moreover, for mostcases, the pooled plasma neutralized the variants from mother and
infant more efﬁciently than the maternal plasma, indicating high
potency and broad speciﬁcity of this plasma pool.
Susceptibility of maternal and infant envelope variants to neutralization
by monoclonal antibody
We also evaluated the susceptibility of thematernal and infant Env
chimera viruses to the monoclonal antibody IgG1 b12 derived from a
subtype B infected individual, which recognizes an epitope over-
lapping the CD4-binding site (Burton et al., 1991; Burton et al., 1994;
Roben et al., 1994) and was shown to be somewhat effective against
the subtype C Env surface subunit as compared to other broadly
neutralizing monoclonal antibodies (Binley et al., 2004; Bures et al.,
2002; Gray et al., 2006; Kulkarni et al., 2009; Li et al., 2006). Our
results indicated that there was a wide range of sensitivity of our
subtype C viruses to IgG1 b12. Themajority of our panel of viruses (30
of the 49, 61%) were resistant to b12 demonstrating less than 50%
neutralization at concentrations up to 25 μg/ml. The most resistant
viruses were those from MIPs 2617, 2873 and 2669 (Table 2). The
IgG1 b12 neutralized 7 of the 24 infant variants tested, with IC50
ranging from 0.6 to 25 μg/ml; whereas 12 of the 25 maternal variants
were neutralized and had IC50 ranging from 0.06 to 25 μg/ml with this
mAb (Table 2). In addition, the interpair differences in susceptibility
to IgG1 b12 were also evident. Notably, for MIP 1984, all the maternal
viruses were more sensitive to neutralization by b12 compared to the
infant viruses, with IC50 values ranging from 0.06 to 0.6 μg/ml for the
maternal viruses whereas 4.3 to N25 μg/ml for the newly transmitted
viruses (Table 2). This is consistent with the observations with
autologous and heterologous pooled plasma for this pair. Similarly,
Fig. 6. Neutralization sensitivity of envelope variants for pooled plasma. (A)
Comparison of neutralization IC50 of maternal (○) and infant (Δ) variants bearing
patient-derived Env V1–V5 region for each transmission pair. A pooled HIV-1 plasma
was tested at a starting dilution of 1:100 as indicated by the dashed horizontal line. The
IC50 from each individual were calculated as in Figs. 5 and compared. The horizontal
bars indicate the median IC50 value for each individual. (B) Comparison of IC50 between
the mother (○) and infant (Δ) variants. The P value of the comparison is shown. The
horizontal bars indicate the median IC50 value. The dashed horizontal line shows the
lowest dilution tested.
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were generally less sensitive to IgG1 b12 than the maternal variants
(IC50 value of 5.3–7.3 μg/ml) although two exceptions (1084M0-1 and
M0-4) were identiﬁed among the nontransmitted viruses. The latter
two maternal viruses were also more resistant to autologous plasma
compared to the rest of the maternal variants. In contrast, variants
derived from infant 1449 showed higher susceptibility to this mAb
than did the mother variants (Table 2), which is different from theTable 2
IC50 values of IgG1 b12 with each maternal and infant variant.
Patient ID Subject Clone ID IC50 (μg/ml)
1984 Mother 1, 2, 3, 4, 5, 6, 7 0.06–0.6
Infant 1 5.6
2, 6 N25
3, 5 25
4 4.3
1084 Mother 1, 4 N25
2 5.3
3 7.3
Infant 1 21.6
2, 3 N25
1449 Mother 2 2.2
3 N25
Infant 1 0.6
2 0.8
2617 Mother 1, 2, 3, 4 N25
5 25
Infant 1, 2, 3, 4 N25
2873 Mother 1, 3, 4 N25
2 1.5
Infant 1, 2, 3, 4 N25
2669 Mother 2, 3, 4 N25
Infant 1, 2, 3, 4, 5 N25results with autologous plasma. When all the variants from six pairs
were considered together, there was a marginally signiﬁcant
difference in the susceptibility to IgG1 b12 between the maternal
and infant variants, with the infant viruses being more resistant than
those of the mothers (P= 0.04; Mann–Whitney test). However, this
difference could be largely due to MIP 1984, where the mother
variants were particularly sensitive (Table 2).
Correlation between neutralization sensitivity and Env genetic
characteristics
Our genetic analysis indicated that infant Env V1–V5 sequences
from ﬁve of the six MIPs have lower mean number of N-linked
glycosylation sites (PNGS) than those of their mothers, suggesting
that viruses harboring Env glycoproteins with fewer potential N-
glycan could be selected during the transmission among these MIPs
(Zhang et al., submitted for publication). In addition, in this study,
we observed that neutralization resistant variants are dominant
among transmitted viruses. We, therefore, further evaluated the
relationship between neutralization sensitivity and the Env genetic
features, such as the length polymorphisms and the number of PNGS
in Env. Aggregate analysis of the Env V1–V5 length from six MIPs
revealed that the acquisition of the Env V1–V5 length was not
signiﬁcantly associated with neutralization susceptibility of these
variants to either the maternal plasma or the pooled plasma
(P= 0.59; P= 0.13) (Figs. 7A and B). However, higher number of
PNGS in this region was found to correlate with greater neutraliza-
tion sensitivity to the maternal plasma but not the pooled plasma
(P= 0.02; P= 0.20) (Figs. 7C and D).
Discussion
Understanding the properties of viruses capable of establishing
infection during perinatal transmission of HIV-1 is critical to guide the
design of vaccines or therapeutics attempting to block transmission.
In this study, viral Env glycoproteins from six anti-retroviral naive
mother–infant pairs were compared for their biological and immu-
nologic properties to discern any parameters that might correlate
with MTCT. To our knowledge, this study represents the ﬁrst detailed
analysis of maternal donor and recipient infant Env biological
properties and sensitivity to neutralization by autologous or heterol-
ogous antibodies in the context of HIV-1 subtype C perinatal
transmission.
We have recently characterized the replicative ﬁtness of these
perinatally transmitted viruses in dual infection competitions. Our
results indicated that infant viruses possess a growth advantage over
those derived from their chronically infected mothers, and the
advantage was conferred by Env V1–V5 region (Kong et al., 2008).
Higher ﬁtnessmay thus enable the transmitted virus to establishmore
efﬁcient propagation at the site of infection in the new host. A number
of factors could affect viral ﬁtness and thereby transmission, including
more efﬁcient processing and incorporation of the transmitted viral
Env. In addition, the ability of the virus towithstand immune selection
pressures such as neutralizing antibodies may also affect the
transmissibility. We therefore tested whether transmitted viruses
were also neutralization resistant or whether a compromise between
immune escape and replication robustness in the new host occurs.
Our analysis of the Env processing or incorporation efﬁciency did
not distinguish between maternal (non-transmitted) and infant
(transmitted) Env; therefore, the efﬁciency of Env processing and
incorporation do not seem to impact the likelihood of subtype C HIV-1
perinatal transmission in our cohort. The slight differences in the
Env's electrophoretic mobility observed in Env processing assay could
indicate the extent of glycosylation among those maternal and infant
Env chimeras. Since glycosylation has a profound effect on the proper
folding, oligomerization and stability of glycoproteins, further studies
Fig. 7. Correlation between neutralization sensitivity and genetic characteristics of the envelope. Neutralization of maternal (○) and infant (Δ) variants was performed with either
maternal plasma (A and C) or pooled plasma (B and D). The IC50 was deﬁned as the dilution of plasma that causes 50% inhibition of virus infection. Amino acid lengths and PNGS in
Env V1–V5 region of the mother and infant variants were calculated. The coefﬁcient r and P values were generated using Spearman's correlation test.
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the biological function of the glycoproteins. Moreover, our study also
indicated that the viral replication kinetics did not differ between
mother and infant variants tested. This is in agreement with a non-
subtype C HIV-1 MTCT, where similar replication proﬁles of the
mother and infant isolates were observed (Kliks et al., 1994).
However, our co-infection growth competition assay of these MIPs
indicated that the transmitted viruses are more ﬁt than their mother's
(Kong et al., 2008), suggesting that differences in viral ﬁtness during
transmission can only be differentiated by direct competition. Indeed,
this has been observed in an earlier study, where the differences in
viral ﬁtness associated with escape from cytotoxic T lymphocytes
between the wild-type and mutant viruses can only be detected by
direct competition assay (Martinez-Picado et al., 2006).
Unlike other modes of transmission, MTCT occurs in the face of
passively acquired maternal antibody before birth. Thus, maternal
neutralizing antibody could impose a selective pressure on the
transmitted virus. We, therefore, examined whether the maternal
nAbs play a role in selecting for the transmissible viruses. Our
observations indicated that for most cases, the transmitted viruses
were less susceptible to neutralization by their baseline maternal
plasma than the contemporaneousmaternal viruses. This is consistent
with previous studies on subtypes A and B perinatal transmission
(Dickover et al., 2006; Kliks et al., 1994; Wu et al., 2006). Kliks et al.
have found that ﬁve of the six infected infants tested harbored viruses
which were less susceptible to their mother's sera (Kliks et al., 1994).
More recently, it has been shown that neutralization escape variants
were favored during subtype A HIV-1 perinatal transmission (Wu et
al., 2006). Similarly, in a study of subtype B MTCT, where in ﬁve of the
seven transmitting mothers with autologous nAbs, the neutralizing
antibody titer to the infant's virus was lower than that of the maternal
isolates (Dickover et al., 2006). Our results indicated that apreferential transmission of neutralizing antibody escape variants
also occurred in the context of subtype C HIV-1 MTCT, supporting the
notion that maternal nAbs exert a preventive and selective effect in
perinatal transmission (Dickover et al., 2006; Kliks et al., 1994; Wu et
al., 2006). Among our study cohort, infants 2873 and 1449 are
characterized as fast progressors and died within the ﬁrst year after
birth; whereas infants 1084 and 1984 were diagnosed as slow
progressors. Our results indicated that sensitivity to neutralization of
the infected infants did not appear to correlate with disease
progression since variants from these infants were, in general,
resistant to the neutralization by their maternal plasma. Collectively,
our observations and those of others suggest that neutralization
insensitive variants are favored during HIV-1 perinatal transmission,
but the transmission of neutralization sensitive variants can still occur
in spite of the presence of maternal neutralizing antibodies. In
addition, our results also indicate that resistance to maternal
neutralizing antibodies is not predictive of disease progression in
the infected children.
Understanding the role of nAbs, including heterologous nAbs, in
MTCT is important for determining whether passive administration of
nAbswill be beneﬁcial. Neutralization analyses employingpooledHIV-1
plasma revealed a higher susceptibility of both maternal and infant
variants although the infant variants appeared to be less susceptible
than the maternal variants, indicating that heterologous neutralization
can be relatively potent. The relatively higher susceptibility of infant
viruses to neutralization by pooledHIV-1 plasma compared tomaternal
plasma indicated that no newly transmitted variants were inherently
resistant to HIV-1 antibody neutralization. This ﬁnding is in agreement
with a previous study on subtypeAHIV-1 perinatal transmission (Wuet
al., 2006). In addition, our observation supports the proposed combined
vaccine/passive monoclonal antibody strategy for prevention of HIV-1
transmission by breast feeding (Dickover et al., 2006).
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bearing the maternal or infant Env could be neutralized by IgG1 b12.
This is similar to a recent study on subtype C HIV-1 from India, where
only 20% of the studied viruses were neutralized by b12 (Kulkarni et
al., 2009). However, these results are somewhat different from those
of several previous studies on HIV-1 subtype C with relative smaller
cohorts, where the IgG1 b12 could neutralized 57–67% of the viruses
tested (Binley et al., 2004; Gray et al., 2006; Li et al., 2006). More
importantly, our ﬁndings indicated that, as a group, the newly
transmitted viruses were likely to be more resistant than their
maternal variants to this mAb although for some pairs both maternal
and infant variants showed similar resistance to this mAb. This
suggests that there could be a selection for altered IgG1 b12 epitope
exposure during the transmission. Viruses harboring Env with under-
represented IgG1 b12 epitopes appeared to be favored during HIV-1
subtype C perinatal transmission. The relative insensitivity of the
newly transmitted viruses to this mAb implies that IgG1 b12may have
limited beneﬁt in preventing HIV-1 subtype CMTCT. This is supported
by a previous subtype C paediatric study with a relative small sample
size from South Africa (Gray et al., 2006). Our data, as well as those of
others, underscore the importance of evaluating newly transmitted
variants in endemic areas when designing neutralizing Ab-based
vaccine immunogens.
Our results of selective perinatal HIV-1 transmission of nAbs
escape variants differs from heterosexual transmission of subtype C
HIV-1 in discordant couples, where viruses with shorter Env V1–V4
and fewer glycans are more susceptible to neutralizing antibodies but
mediate more efﬁcient heterosexual transmission (Derdeyn et al.,
2004). These patterns, however, have not been conﬁrmed in subtype
B sexual transmission (Chohan et al., 2005; Frost et al., 2005a; Frost et
al., 2005b), but viruses with shorter V1–V2 length and reduced
sequons have been reported in a subtype A heterosexual transmission
study (Chohan et al., 2005). The discrepancy in viral characteristics,
including genotypic and phenotypic parameters, leading to preferen-
tial transmission of particular Env variants between sexual and
perinatal transmission studies could be due to fundamental differ-
ences in the mode of transmission or due to subtype-speciﬁc
virological factors. For sexual transmission, the mucosal barrier is
likely to be a major constraint on the transmitting virus, while
perinatal transmission is also affected by the presence of passively
transferred maternal neutralizing antibodies (Derdeyn and Hunter,
2008; Haaland et al., 2009).
We also investigated the Env genetic characteristics associated
with the neutralization proﬁles of these variants. We found that
acquisition of Env N-glycan of the mother and infant's sequences
correlated with the enhanced neutralization susceptibility of these
variants to the maternal plasma. This was somewhat unexpected
given that neutralization resistance is generally linked to increased
PNGS in viruses that evolve during chronic infection (Cheng-Mayer et
al., 1999; Wei et al., 2003). Therefore, it is likely that different
mechanisms could be involved in determining the neutralization
phenotype of the virus in the cases of subtype C perinatal
transmission. Further studies will be needed to evaluate how the
changes in Env N-glycan affect the neutralization outcome of the
viruses during perinatal transmission. Different from a subtype A
perinatal transmission study (Wu et al., 2006), where greater
sensitivity to maternal plasma neutralization was shown to correlate
with shorter variable loops in Env sequence, we did not observed any
correlation between the Env length and neutralization sensitivity in
our cohort. However, acquisition of length in Env V1–V4 region of
donor and recipient's sequences were linked to enhanced neutraliza-
tion resistance to the autologous or heterologous antibodies in the
cases of subtype C HIV-1 heterosexual transmission (Rong et al.,
2007). Therefore, our results, together with those from others,
highlight the need to further explore genetic and immunologic
correlates of different subtypes and different routes of transmission.In summary, our data, though limited in sample size, suggests that
both viral and immunologic factors, including Env glycosylation status
(Zhang et al., submitted for publication), viral replication ﬁtness
(Kong et al., 2008), and maternal nAbs play a role in subtype C HIV-1
perinatal transmission. Variants with the characteristics of higher
replication ﬁtness, resistance to maternal nAbs and reduced glyco-
sylation in Envwere preferentially transmitted through thematernal–
infant bottleneck during subtype C HIV-1 transmission. In addition,
the newly transmitted variants were relatively sensitive to neutral-
ization by pooled heterologous plasma, but most of them were
resistant to IgG1 b12. Moreover, neither Env processing nor
incorporation efﬁciency was predictive of viral transmissibility.
These ﬁndings provide further insights for unraveling selective
pressures that occur during HIV-1 perinatal transmission and may
have implications for pediatric vaccine design and prevention of
perinatal transmission.
Materials and methods
Patient information and sample collection
Six MIPs labeled 2617, 1449, 1084, 2669, 2873, 1984 from our
previous study (Zhang et al., 2006) were characterized in the study.
The mothers were known to be HIV-1 positive at the time of delivery
and all subjects were asymptomatic and were not yet eligible for ART
at the time. The babies were all breast-fed and drug naive. Maternal
samples at delivery were deﬁned as baseline and infant baseline
samples were referred to the ﬁrst postpartumHIV-1 PCR positive time
point. The baseline HIV-1 serological status of the mother and HIV-1
infection in infants was determined as previously described (Zhang et
al., 2006).
Cell cultures
293 T, COS-1 and TZM-bl ( NIH AIDS Research and Reference
Reagent Program catalog no. 8129) cells were maintained in
Dulbecco's modiﬁed Eagle medium (DMEM) with 10% fetal bovine
serum (FBS, Hyclone), 100 U/ml penicillin and 100 μg/ml strepto-
mycin. PBMCwere puriﬁed using Lymphoprep (Life Technology) from
a HIV-seronegative donor and then propagated in RPMI 1640
containing 10% FBS, 100 U/ml penicillin, 100 μg/ml streptomycin
and 5 μg/ml of phytohemagglutinin (Sigma, St. Louis, MO) for 40 h
before being infected with viruses.
Env glycoprotein expression constructs and proviral expression
constructs
The V1–V5 region of env gene was ampliﬁed by nested PCR from
uncultured patient PBMC, cloned into the pGEM-T Easy vector and
sequenced as described previously (Zhang et al., 2006). The pre-
existing, genetically characterized Env V1–V5 clones were used as the
source of genetic materials for generation of the Env chimeras.
Approximately 20 representative Env clones, based on Env V1–V5
length and putative N-glycan number, as well as sequence diversity,
were selected from each MIP baseline viral population (Kong et al.,
2008). The Env V1–V5 region from selected clones was ampliﬁed from
the pGEM-T Easy vector by using primers containing restriction
enzyme sites DraIII and AvrII: sense primer C-DraIII (5′-TGACCC-
CACTCTGTGTCACTTTA-3′) and antisense primer C-AvrII (5′-CTATTCC-
TAGGGGCTTAATTTCTACCACTT-3′). The resulting PCR products were
subcloned into a shuttle vector, pSP72 NLA/S/Av, using the restriction
enzyme sites DraIII and AvrII. The pSP72 NLA/S/Av was generated by
introducing the envelope gene of pNL4-3 modiﬁed with AgeI/SbfI/
AvrII by silent mutation into a cloning vector, pSP72 (Promega) and
was used for the sequential cloning of patient V1–V5 region of env
gene into an Env expression vector, pSRH NLA/S/Av. This vector was
172 H. Zhang et al. / Virology 400 (2010) 164–174generated by modifying the mammalian expression vector pSRH
which contains an SV40 promoter and reading frames for NL 4-3 Tat,
Rev and Env (kindly provided by Dr. Eric Hunter, Emory University).
The chimeric Env expression construct containing patient-derived
Env V1–V5 region was generated by substituting EcoRI–XhoI region of
pSP72 NLA/S/Av with the corresponding region of pSRH NLA/S/Av.
All the patient-derived chimeric Env expression constructs were ﬁrst
screened for biological function using the fusion assay. Brieﬂy, 2×104
COS-1 cells per well grown in 24-well plates were transfected with
0.5 μg of the patient-derived Env glycoprotein expression plasmid.
Twenty-four hours subsequent to transfection, 5×104 of the TZM-bl
(target) cells were added onto the Env expressing COS-1 (effector)
cells. The effector and target cells were allowed to fuse for 24 h. The
cells were stained for β-galactosidase expression and the fusion level
was determined by the number of blue foci. Between 30% and 70% of
the selected clones were biologically functional. Finally, the functional
envelope construct was transferred into a proviral expression vector-
pNL4-3 A/S/Av, with NL4-3 viral backbone, by substituting EcoRI–
XhoI region of pSRH NLA/S/Av with the corresponding region of
pNL4-3 A/S/Av, resulting in the infectious molecular clone plasmids.
Between 4–13 representative Env clones from each MIP baseline viral
population were available for the functional assays as described
below.
Virus stocks
NL4-3 or chimeric viruses bearing patient-derived Env V1–V5
region were produced by transfection of 293 T cells with proviral
constructs. Nine μg of proviral construct was transfected into 2.2×106
293 T cells using Fugene 6 (Roche). The resulting infectious viruses
were harvested 48 h post-transfection, ﬁltered through 0.45 μm ﬁlter
and stored at -80 °C. The tissue culture dose for 50% infectivity
(TCID50) was determined for each recombinant virus in TZM-bl cells.
Viral titer was deﬁned as TCID50/ml.
Co-receptor usage and cell tropism
Co-receptor usage and cell tropism were deﬁned using Ghost cell
lines that express speciﬁc co-receptors and MT-2 cells as described
previously (Zhang et al., 2005).
Synthesis and processing of Env glycoproteins
The kinetics of glycoprotein synthesis and processing were
analyzed by pulse-chase as described previously (West et al., 2002)
with somemodiﬁcations. Brieﬂy, 1.3×106 COS-1 cells grown in 10-cm
culture dishes were transfected with 9 μg of each Env expression
construct. At 24 h post-transfection, cells were dissociated from the
plate and divided into 6-well plates at a density of 9×105 transfected
cells per well to allow the cells to grow overnight. COS-1 cells
expressing NL4-3 Env protein or chimeric Env proteins bearing
patient-derived Env V1–V5 region were starved for 40 min with
DMEMCys/Met-freemedium and pulse-labeledwith [35S]methionine
for 45 min at 37 °C. The pulse-labeled cells were then chased in
complete medium for 2, 6 and 24 h, respectively. At the completion of
the chase, the culture supernatant was collected, ﬁltered through a
0.45-μm syringe ﬁlter and lysed with lysis buffer to a ﬁnal
concentration of 1% NP40, 0.1% SDS, 0.5% deoxycholic acid sodium
salt and 10 μl/ml Halt Protease Inhibitor Cocktail (Pierce). To prepare
cell lysates, cells were washed twice with ice-cold phosphate-
buffered saline (PBS) and lysed in the buffer described above on ice.
The cell lysates were clariﬁed by centrifugation at 20,000×g for 1min.
The clariﬁed cell lysates and supernatants were immunoprecipitated
with pooled subtype C HIV-1 infected patient serum. Viral proteins
were resolved on 8% SDS-PAGE and visualized by autoradiography.Glycoprotein incorporation into virions
To determine the level of viral envelope glycoprotein incorporated
into virus particles, 293 T cells were transfected with the proviral
constructs. Brieﬂy, 2.2×106 293 T cells grown in 10-cm culture dishes
were transfected with 9 μg of each proviral construct. At 48 h post-
transfection, viral supernatants were harvested and ﬁltered through
0.45 μm ﬁlters. A fraction was kept for p24 quantiﬁcation and
infectivity assay, and the remaining virus-containing supernatant was
centrifuged to pellet the virus at 65,000 rpm (Beckman, Type 90 Ti)
through a 20% (wt/wt) sucrose cushion for 2 h at 4 °C. The resulting
pellet was lysed for SDS-PAGE analysis. Viral proteins were separated
by SDS-PAGE, blotted onto PVDF membranes (Amersham Bios-
ciences) and analyzed by Western blotting using monoclonal
antibody (mAb) 2F5 (Polymun Scientiﬁc Inc., Vienna, Austria) to
detect gp41, or anti-p24 mAb (NIH AIDS Research and Reference
Reagent Program, Cat. No. 1513) to detect p24. Protein quantiﬁcation
was performed using a Fluor-S™ Multilmager (BIORAD).
Viral infectivity assay
The p24 content of each virus stock from transfected 293 T cells
was determined using HIV-1 p24 ELISA kit (Perkin-Elmer Life
Sciences, Inc.). Two ng of p24 of each virus was used to infect
2×104 TZM-bl target cells in triplicates in the presence of 40 μg/ml of
DEAE-dextran in a 96-well plate. At 48 h post-infection, cells were
lysed and luciferase activity was measured using the Luciferase Assay
System (Promega, Madison, WI). Luciferase activity was measured
using a LUMIstar Luminometer (BMG Lab Technologies, Offenburg,
Germany). Background luminescence in uninfected wells was
subtracted from all experimental wells. Relative infectivity was
calculated by comparing the luciferase activity between the patient-
derived chimeric virus and the NL4-3 infected cells.
Replication kinetics of chimeric viruses
For replication kinetics in TZM-bl cells, equivalent infectious units,
200 TCID50, of each chimeric viruses from transfected 293 T cells were
added to duplicate wells in a 48-well plate containing 2×104 TZM-bl
cells per well. After incubation at 37 °C overnight, cells were washed
three times with medium and 500 μl of fresh medium was added. A
250 μl aliquot of each infected culture was sampled on day 0, 2, 4, 6, 8,
10, 12 and 14, and the culture was replenished with an equal volume
of fresh medium. In order to determine viral yield at each timepoint,
75 μl of each collected culture supernatant was used to infect 2×104
TZM-bl cells in a 96-well plate. At 48 h post-infection, cells were lysed
and luciferase activity was determined as described above.
Neutralization assays
The susceptibility of the chimeric viruses bearing patient-derived
Env V1–V5 region to neutralization by maternal or pooled plasma or
mAb IgG1 b12 (Polymun Scientiﬁc Inc., Vienna, Austria) was assayed
in the TZM-bl cells in 96-well plates as described previously
(Monteﬁori, 2004; Zhang et al., 2005) with some modiﬁcations.
Brieﬂy, 20 TCID50 of each provirus (in 50 μl) was incubated with equal
volumes of threefold serial dilutions of IgG1 b12 or heat-inactivated
plasma, or with growth medium alone at 37 °C for 1 h in the presence
of 1 μM Indinavir and 40 μg/ml of DEAE-dextran. The virus–plasma or
virus–antibody mixture was then added to TZM-bl cells in triplicate
for an additional 3 h at 37 °C. Thereafter, 50 μl of medium was added
to each well, and the cells were incubated at 37 °C for 2 days. After 2
days, the cells were washed once with PBS, lysed and the luciferase
activity of each well was measured as described above. Background
luminescence in uninfected wells was subtracted from all experi-
mental wells. Differences between the luciferase activity in the
173H. Zhang et al. / Virology 400 (2010) 164–174presence of plasma or antibody and growth medium alone were
calculated as the percentage of antibody neutralization. The IC50 was
deﬁned as the reciprocal dilution of plasma or the concentration of the
IgG1 b12 that causes 50% inhibition of virus infection and was
calculated using GraphPad Prism software version 5.0 (GraphPad
Software, Inc., San Diego, CA) . Maternal plasma and pooled plasma
from 50 HIV-1 subtype C infected Zambian patients were tested at a
starting dilution of 1: 50 and 1:100, respectively. The mAb IgG1 b12
was tested at a starting concentration of 25 μg/ml.
Statistical analysis
All statistical tests were performed with GraphPad Prism software
version 5.0. In cases in which the IC50 for maternal plasma was b50,
the midpoint value between 0 and 50, 25, was assigned for statistical
analysis. For mAb IgG1 b12, the IC50 value of 25 was used when there
was b50% neutralization at the highest concentration (25 μg/ml)
tested. Signiﬁcance was reported when P≤0.05, and a trend was
reported when 0.05bP≤0.1. Correlation of neutralization IC50 to the
Env V1–V5 length and N-glycosylation sites was examined with
Spearman's correlation test.
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